BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Biopharma M&A scorecard
BioWorld 2024 review
BioWorld MedTech 2024 review
BioWorld Science 2024 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Tuesday, April 22, 2025
See today's BioWorld Asia
See today's BioWorld MedTech
See today's BioWorld
Home
» Australia’s Cyclopharm raises AU$30M ahead of U.S. launch of Technegas for pulmonary embolism
To read the full article
sign up for free
or
sign in
.
Australia’s Cyclopharm raises AU$30M ahead of U.S. launch of Technegas for pulmonary embolism
Jan. 26, 2021
By
Tamra Sami
PERTH, Australia – Sydney-based Cyclopharm Ltd. raised AU$30 million (US$23.19 million) in a private placement that will enable the company to launch its Technegas combination product in the U.S.
BioWorld
BioWorld MedTech
BioWorld Asia
Financings
Coronavirus
Private
Asia-Pacific
Australia